Chinese Pharmaceutical Industry Research Paper Example | Topics and Well Written Essays - 2000 words

Chinese Pharmaceutical Industry - Research Paper ExampleTheses firms are to boot required to set aside a stripped-down of 5.5% of the conglomeration revenue for R&D expenses. This abduct province necessitates a minimum expenditure of 4%, on similar lines to the Fuji Province which necessitates that the minimum R&D expenditure for such firms should be 5%, an increase of 2% from the earlier 3% prior to 1999.On similar lines, different provinces tin different benefits to the HTIE, with the basic structure remaining the same. These Articles of different provinces outline several benefits including revenue enhancement reductions, discounts on capital purchase, lending support by the government and opposite operation priorities related to the pharmaceutical HTIE units.The Shenzhen Article 2.2 gives numerous benefits to HTIE units that have operated for more than a decade. The government promises that the income tax for the first and the second year of operation would be waived off c ompletely, and would be reduced by cubic decimeter portion by the time they reached the eighth year of functioning. Article 2.3 states that for products concerning National innovation, twenty-five percent of the total share of the local government tax should be returned by a minimum of fifty percent by the municipal government for three years in a row. Article 3.3 further affirms that monetary support as debt would be provided by the government to the tune of twenty percent to the HTIE firms. Article A-4.2 assures a discount between ten-twenty percent on rent and A-13.5 assures HTIE firms to have a priority on exports. Article-A/10 reduces the taxes on R&D expenditure. Although the basic vision and goals of the provinces remain the same, slight differences occur in impairment of percentage numbers among the provinces of Shanghai, Fuji, Shangxi and the Zhejiang. The role of the government in supporting the HTI Enterprises is obvious by the measures taken to provide aid and suppor t to these enterprises. However, the benefits mentioned in the Articles are applied universally, as a whole to diverse industries, including teaching Technology, Bio-technology, Modern agriculture, Environment protection along with the Pharmaceutical Industry (Article 5, Shanghai, 2001-7-2). The government ignores the fact that the pharmaceutical and bioengineering perseverance play a crucial role in R&D spending with roughly fifty leading Chinese global firms spending 16.4% of their total revenue on R&D activities whereas only four-to-six percent was set aside for the HTIE qualified units in China. The figure of 4-6& is understandably sufficient for separate industries innovation and development, but not so for the Pharmaceutical industry. It is therefore necessary to segregate the Pharmaceutical industry from the HTIE, providing it with a distinct status and consequently separate substantial waivers and rewards by the government for these actual modern Pharmaceutical enterpr ises to flourish and prosper. Price CeilingIn China, the unequal distribution of medication is a overserious social problem because of the differences in the price of drugs and regional incomes. In the year 2000, China ranked quaternary last among 191 countries of WHO with regard to health service equality and accessibility. The 2003 national health census, confirmed that 48.9%